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Transcatheter Mitral Valve 




We will review transcatheter mitral valve replacement (TMVR) and discuss this 
evolving cutting edge procedure in terms of types (valve in valve, valve in ring and 
valve in mitral annular calcification MAC), clinical indications, pre-procedural 
planning and value of pre-procedural imaging including computed tomography 
role, technical challenges encountered in these procedures, potential complications 
for each type of TMVR, and potential strategies to mitigate and avoid such compli-
cations, We will review the currently available devices dedicated for mitral valve 
replacement, with a summary of their preliminary data and early outcome results. 
We will also discuss knowledge gaps and ideas for future research.
Keywords: Transcatheter mitral valve replacement, valve in valve, valve in ring,  
valve in mitral annular calcification
1. Introduction
Valvular heart disease affects >100 million patients worldwide, which is 
estimated to increase further with the aging population and a subsequent increase 
in degenerative valve disease [1]. Based on analysis of the Society of Thoracic 
Surgery (STS) National Database, there are >40,000 mitral valve replacements 
being performed annually in the United States (US), with shift from mechanical 
to bioprosthetic valve replacements [1]. It is known that redo mitral valve surgery 
is associated with higher mortality compared to first mitral surgery; with 30-day 
mortality ranging from 6% for elective second mitral valve surgery and 17.8% for 
emergency surgery [2]. The risk of a third or fourth surgery is even higher; with 
30-day mortality reaching up to 44% in urgent surgery [3]. As such, Transcatheter 
mitral valve replacement (TMVR) using aortic balloon-expandable transcatheter 
heart valves (THV) has been increasingly performed for patients with severe 
mitral valve disease who are not candidates for surgery [4]; as it emerged as a less 
invasive alternative option for these patients with relatively lower mortality than 
the predicted STS predicted rates of mortality [4]. Moreover, dedicated devices for 
TMVR have been developed and some are currently being studied [5–10]. Results 
of the clinical outcomes of TMVR are promising, but anatomical differences 
between mitral bioprosthetic valves, annuloplasty rings, and severely calcified 
mitral annulus are associated with specific procedural challenges for TMVR 
procedures [1, 4].
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2. Types of TMVR
There are three main types of TMVR: 1) valve-in-valve (ViV) for severe mitral 
valve disease due to degenerated mitral bioprosthetic valves, 2) valve-in-ring (ViR) 
for failed surgical repairs with annuloplasty rings, and 3) valve-in-mitral annular 
calcifications (ViMAC) for native mitral valve disease with severe MAC who are 
poor surgical candidates [1]. Mitral ViV for high surgical risk patients was approved 
by the Food and Drug Administration (FDA) in the United States (US) in 2017, 
while mitral ViR and ViMAC remain off-label at this current time [4]. The role of 
TMVR in native mitral valve disease, whether MR or mitral stenosis, is currently 
being studied using various device types and designs. We will discuss these sepa-
rately under the dedicated TMVR device section.
3. Scientific evidence supporting TMVR
The scientific evidence supporting TMVR is based on observational data, mostly 
from registries, in North America and Europe [1, 4–15], summarized in Table 1. 
Several studies showed data on outcomes of mitral ViV, ViR, ViMAC from single or 
multi-center registries; with consistent results demonstrating overall better out-
comes for mitral ViV procedures compared to mitral ViR and ViMAC [1, 4–15].
The role of mitral ViV, ViR, and ViMAC has been evaluated in a prospec-
tive early feasibility clinical trial, the MITRAL trial (Mitral Implantation of 
Transcatheter Valves, NCT 02370511), which is the first prospective study assessing 
outcomes of TMVR in all of the three separate subtypes. The results of the trial have 
been recently published [16–18].
Author, year published Number of patients Major outcomes
Guerrero et al. [11] 64 patients with ViMAC • Technical success was 72%
• 30-day all-cause mortality was 29.7%
• 84% of the survivors with follow-up data 
available were in New York Heart Association 
(NYHA) class I or II at 30 days
Yoon et al. [13] 248, 176 patients 
undergoing ViV, 72 
patients undergoing ViR
• ViR had lower technical success (83.3% vs. 
96.0%; p = 0.001) due to more frequent second 
valve implantation (11.1% vs. 2.8%; p = 0.008)
• ViR had higher 1-year all-cause mortality rate 
(28.7% vs. 12.6%; log-rank test, p = 0.01).
Eleid et al. [14] 87 patients (ViV = 60, 
ViR = 15, ViMAC = 12)
• Procedural success was 97% in ViV, and 74% in 
ViR and ViMAC.
• 30-day survival free of death and cardiovas-
cular surgery was 95% in ViV and 78% in ViR 
and ViMAC
• 1-year survival free of death and cardiovascu-
lar surgery was 86% in the ViV compared with 
68% in ViR and ViMAC
Guerrero et al. [5] 106 patients with MAC • 30-day and 1-year all-cause mortality was 25% 
and 53.7%, respectively.
• Most patients who survived 30 days were 
alive at 1 year and majority were in NYHA 
functional class I or II
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In the MITRAL trial, in which 30 patients undergoing transseptal mitral ViV 
were enrolled between July 2016 and October 2017, technical success was achieved 
in 100% of cases with 30-day all-cause mortality of 3.3%, which remained 
unchanged at 1 year. At 1-year follow-up, the vast majority of patients were in New 
York Heart Association (NYHA) functional class I or II [16].
Similarly, in the MITRAL trial assessing patients undergoing transeptal mitral 
ViR, 30 patients were studied with results showing technical success of 66.7% 
(driven primarily by need for a second valve in 6 patients), all-cause mortality 
of 6.7% at 30 days and 23.3% at 1 year. Similar to ViV study, the vast majority of 
patients were in NYHA class I or II at 1 year [17].
MITRAL trial assessed ViMAC by prospectively enrolling 31 patients and 
was challenged by a high proportion of patients with threatened left ventricular 
outflow tract (LVOT) obstruction. As such mitigation strategies were devise in the 
form of alcohol septal ablation and trans-atrial valve implantation accompanied by 
anterior leaflet resection. As such as high proportion of patients received trans-
atrial TMVR (48.4%), while transseptal access was used in 48.4%, and transapi-
cal access 3.2%. Technical success was achieved in 74.2% of cases, overall 16.7% 
(trans-atrial, 21.4%; transseptal, 6.7%; transapical, 100% [n 1/4 1]; p = 0.33) 
all-cause mortality rate at 30 days and 34.5% (trans-atrial, 38.5%; transseptal, 
26.7%; p = 0.69) mortality at 1 year. Similar to ViV and ViR study, the vast majority 
of patients were in NYHA class I or II at 1 year [18]. Importantly, this trial intro-
duced preemptive alcohol septal ablation as a mitigation strategy to prevent LVOT 
obstruction [18].
Author, year published Number of patients Major outcomes
Urena et al. [12] 91 patients (ViV 37.3%, 
ViR in 33.0%, and 
ViMAC in 29.7%)
• mortality rate at 30 days was 7.7% without 
significant differences between groups
• The cumulative rates of all-cause mortality at 
1-year and 2-year follow-up were 21.0% and 
35.7%, respectively, with higher late mortality 
in patients with MAC.
Yoon et al. [1] 521 patients (322 ViV, 
141 ViR, and 58 ViMAC)
• ViMAC was associated with higher all-cause 
mortality in comparison to ViR and ViV 
at follow up of 30 days (34.5% vs. 9.9% vs. 
6.2%; log-rank P < 0.001) and 1 year  
(62.8% vs. 30.6% vs. 14.0%; log-rank  
P < 0.001).
Werner et al. [15] 7 patients (3 ViV, 1 ViR, 
3 ViMAC)
• clinical success with functional improvement 
of at least one NYHA class was achieved in all 
patients with in-hospital mortality rate of 14% 
(1/7)
• After hospital discharge, no death occurred, 
and clinical improvement remained stable at 
1 year
Guerrero et al. [4] 903 patients (680 ViV, 
123 ViR, 100 ViMAC)
• Technical and procedural success were higher 
in ViV.
• In-hospital mortality (ViV = 6.3%, ViR = 9%, 
ViMAC = 18%; P = 0.004) and 30-day mortal-
ity (ViV = 8.1%, ViR = 11.5%, ViMAC = 21.8%; 
P = 0.003) were higher in ViMAC.
Table 1. 
Summary of observational TMVR studies with their major outcomes.
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4. Procedural planning
Successful TMVR depends on accurate sizing of the mitral annulus and avoid-
ance of LVOT obstruction. In the absence of a validated standard method for mitral 
annulus sizing at the present time, operators have extrapolated from transcatheter 
aortic valve replacement (TAVR) experience and used a variety of sizing approaches 
including echocardiography, 3-dimensional (3D) transesophageal echocardiog-
raphy, cardiac CT, and balloon sizing techniques [10]. Cardiac CT is the most 
accepted imaging modality for annulus sizing. In general, pre-procedural imaging 
constitutes of contrast-enhanced CT to identify critical cardiac structures and 
anatomy, including sizing of the mitral annulus, which is the basal-most structure 
of the mitral leaflets [19]. In addition to annular sizing, CT also provides essential 
information for pre-procedural planning, including the amount and distribution of 
calcifications, as well as predictors of LVOT obstruction; the left ventricular cavity 
size, anterior leaflet length, aorto-mitral angulation, septal hypertrophy, among 
other features. CT is also helpful in identifying the trajectory and site of access, 
whether transapical or transseptal [10, 19].
Data utilizing 2-dimensional (2D) echo imaging correlated acute angulation 
of the mitral aorta-outflow-angle (mAOA) with higher risk of LVOT obstruction 
compared with that of more obtuse mAOA. However, risk of LVOT obstruction is 
not solely based on mAOA; this is because LVOT is a 3D anatomical structure and 
mAOA on 2D echo images may not provide the comprehensive assessment needed. 
CT overcomes this limitation as it provides a 3D assessment. Both the prosthetic 
valve and the anterior displacement of anterior mitral leaflet can result in severe 
LVOT obstruction. Additionally, utilization of computer-aided designs and 3-D 
printed models allows us to test devices in patient-specific anatomy and at different 
angulations and depths with estimation of risk for LVOT obstruction [19].
LVOT obstruction is a fatal complication; thus, pre-procedural planning in an 
attempt to predict neo-LVOT provides a key step in the success of TMVR procedure. 
In a multicenter study of 38 patients undergoing TMVR using balloon-expandable 
valves for severe mitral valve dysfunction because of degenerative surgical mitral 
ring, bio-prosthesis, or severe native mitral stenosis from severe mitral annular 
calcification, the investigators defined LVOT obstruction as increase of 10 mmHg 
or more in LVOT peak gradient following TMVR and found that 7 of the 38 patients 
had LVOT obstruction, with CT neo-LVOT surface area correlating well with 
measurements after TMVR [20]. Yoon and colleagues in their study of 194 patients 
undergoing TMVR found that LVOT obstruction was associated with higher 
procedural mortality compared with patients without LVOT obstruction (34.6% vs. 
2.4%; p < 0.001) [21].
5. Technical considerations
The first few TMVR procedures were performed using a surgical transapical  
[6, 7] or open trans-atrial [8, 9] approach, but subsequent reports described success-
ful implantation with a completely percutaneous trans-femoral transseptal approach 
[10–12]. Transseptal access has been the default access in ViV and ViR in the 
MITRAL trial, while both transseptal and trans-atrial access have been equally used 
in ViMAC [16–18]. All-cause 30-day mortality in ViMAC was 16.7% (trans-atrial, 
21.4%; transseptal, 6.7%; transapical, 100% [n = 1]; p 0.33) and 1-year mortality 
was 34.5% (trans-atrial, 38.5%; transseptal, 26.7%; p = 0.69) [18]. These mortality 
rates are relatively higher than other transeptal or transapical procedures; as stud-
ies have shown that the 30-day and 1-year mortality rates were 3.6% and 23.2% for 
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patients undergoing transseptal transcatheter edge-to-edge repair using MitraClip 
for secondary mitral regurgitation, and the 30-day and 1-year mortality rates were 
8.4% and 25.4% for transapical TAVR [22, 23].
Because the mitral annulus is larger in size compared to aortic valve annulus, 
TMVR requires larger devices, including prosthesis and delivery systems [10]. Mitral 
annular calcifications are less common compared with aortic valve calcifications, 
and their presence may condition the implant of a transcatheter mitral prosthesis. 
For this purpose, the role of TMVR in presence of considerable annular calcification 
is less clear, as shown in the MAC (mitral annular calcification) Global Registry, 
which demonstrated that TMVR was feasible in MAC but associated with relatively 
high early and midterm mortality at 1 year, although patients who survived at 1-year 
follow-up had sustained improvement of symptoms [4, 5]. Similarly, the MITRAL 
trial showed relatively high 1-year mortality in ViMAC patients, but transeptal 
ViMAC showed promising results with 30-day mortality lower than the predicted STS 
score, however mortality rates in this population remains higher than other transeptal 
procedures, including transcatheter edge-to-edge repair using MitraClip [1, 2, 18].
6. Procedural complications
6.1 ViV
Complications in ViV are considered relatively low, with reported LV perfora-
tion 0.4%, LVOT obstruction 0.7% and conversion to surgery in 1.3% [1, 4]. 
Post-procedure mitral valve function was excellent with a median mean mitral 
valve gradient of 4 mm Hg and residual mitral regurgitation grade of 1+ or less in 
98.1%. A second valve was needed in a relatively small proportion of mitral ViV 
patients (1.5%) and was associated with higher mortality at 30 days. The reasons 
or mechanisms for which this was associated with higher mortality (residual mitral 
regurgitation, thrombosis, renal failure) are not known at this time [4].
6.2 VIR
Generally speaking, studies have shown that ViR TMVR is associated with 
worse outcomes compared with ViV, but better outcomes compared with ViMAC 
procedures [1, 4, 10, 16–18]; ViR is a more complex procedure than ViV due to the 
different types of rings (rigid versus nonrigid, complete versus incomplete) and 
different shapes, which are usually not round predisposing to residual paravalvular 
leak [1, 4]. There are 3 main challenges in ViR cases: valve anchoring, LVOTO and 
paravalvular leak. Yoon et al. showed that ViR had a significantly lower technical 
success rate compared with the ViV group (83.3% vs. 96.0%; p = 0.001) due to 
more frequent second valve implantation (11.1% vs. 2.8%; p = 0.008) [1]. Moreover, 
the investigators found that residual mitral regurgitation moderate or higher at 
30 days was more frequent in patients with flexible rings compared with those with 
semi-rigid rings (44.4% vs. 10.8%, p = 0.02) [1]. A study showed that the 30-day 
mortality was 11.5% in ViR patients with median STS PROM score of 9.3% [4]. The 
reasons for higher mortality in mitral ViR are probably multifactorial; potentially 
related to higher procedural complication rates including LVOT obstruction, higher 
valve embolization rate, residual mitral regurgitation and need for reintervention 
including conversion to surgery, as well as different baseline characteristics includ-
ing a lower baseline left ventricular ejection fraction [4]. In fact, the ViR group also 
had the highest rate of device embolization at 30 days 3.6% compared with mitral 
ViV 0.2% and ViMAC 1.6% [4].
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Guerrero et al. showed 4.9% rate of LVOT obstruction in ViR, which was lower 
than the 8% in the VIVID registry; this could be related to increased experience in 
patient selection and risk-reduction strategies. Overall, mitral ViR is observed to 
have higher rates of LVOTO as compared to ViV, possibly due to the presence of a 
preserved anterior mitral leaflet. In most ViV cases, the anterior leaflet is no longer 
present making LVOT obstruction less likely [4].
Guerrero et al. also demonstrated that when comparing outcomes by types of 
rings (complete versus incomplete, rigid versus nonrigid), there was a larger mitral 
valve area in incomplete rings versus complete rings [4]. However, there was no 
statistically significant difference in median mean mitral valve gradients and clini-
cal outcomes between the groups based on the type of ring [4].
6.3 ViMAC
Studies have shown that ViMAC procedures were associated with the lowest 
technical success and the highest in-hospital and 30-mortality compared with 
mitral ViR and ViV [1, 4]. Similar to ViR, ViMAC has significant challenges to 
anchoring, paravalvular leak and LVOTO. The reasons are multifactorial, including 
presence of multiple comorbidities and technical challenges including the complex-
ity of the mitral valve anatomy; as the native mitral valve is a saddle oval shape 
being treated with a round transcatheter valve which may lead to paravalvular leak 
at commissures, non-uniform calcium distribution, and relatively small sized ven-
tricles accompanied by threatened LVOTO [1, 4, 10]. Therefore, there is a frequent 
need for LVOT modification taking the form of three options: LAMPOON, Alcohol 
septal ablations or surgical resection of the anterior leaflet.
LVOT obstruction is considered the Achilles’ heel of TMVR, especially in 
ViMAC. It has limited treatment options and was the strongest predictor of 30-day 
and 1-year mortality in the TMVR in MAC Global Registry [4, 5, 10]. Studies have 
shown that LVOT obstruction rate in ViMAC procedures is at least 10% [1, 4, 5, 10]. 
One factor that could contribute to different rates of LVOT obstruction observed 
among registries may be the different definitions used, such as LVOT obstruction 
with hemodynamic compromise versus increase in mean LVOT gradient of ≥10 mm 
Hg from baseline. Another important factor may be improved screening process 
with cardiac computed tomography to predict LVOT obstruction and strategies to 
prevent it [1, 4]. Potential predictors of LVOT obstruction are the angle of the mitral 
valve in relation to the LVOT long axis, the presence of small LV cavity, bulging or 
severe hypertrophy of the basal interventricular septum, long anterior mitral valve 
leaflets, dynamic alterations as the pushing of the native anterior leaflet toward the 
LVOT, prosthesis protrusion and device flaring [4, 5, 10, 19–21].
7. Strategies to mitigate procedural complications
Cardiac computed tomography to measure the expected neo-LVOT area to assess 
the risk of TMVR-induced LVOT obstruction identifying patients at risk facilitates 
implementation of measures to decrease such risk including preemptive alcohol 
septal ablation, percutaneous laceration of the anterior mitral leaflet, surgical 
excision of the anterior mitral leaflet during trans-atrial TMVR or deciding not to 
perform the procedure at all [1, 4, 10, 24, 25].
Several strategies to prevent or treat LVOT obstruction caused by TMVR have 
been developed and studied. These strategies include: 1) preemptive alcohol septal 
ablation in patients at risk for TMVR-induced LVOT obstruction who have favorable 
anatomy for alcohol ablation as shown in the MITRAL trial [18], 2) percutaneous 
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laceration of the anterior leaflet to decrease the risk of TMVR-induced LVOT 
obstruction in TMVR procedures (The LAMPOON trial; Laceration of the Anterior 
Mitral Leaflet to Prevent Outflow Obstruction During TMVR) [24, 25], 3) possibly 
trans-atrial surgical access for TMVR in severe MAC, as evaluated by the SITRAL 
Trial (Surgical Implantation of Transcatheter Valves) [1, 4, 24, 25].
8. Dedicated TMVR devices
In addition to the balloon expandable valves which were initially designed for 
the aortic valve and have been used in mitral valve interventions, several valve 
designs dedicated to the mitral valve have been developed and studied in several 
studies with a relatively small number of patients, with some promising results [10]. 
These dedicated mitral valves are summarized in Figure 1 and Table 2.
The CardiAQ (Edwards Lifesciences Inc) valve is a nitinol self-expanding tri-
leaflet valve, composed of bovine pericardial tissue, which was the first dedicated 
device for TMVR in 2012 in high-risk patients with severe MR. This was followed 
by the second generation of the valve, which was used for the first time in 2014 
[26]. The new redesigned version was renamed as the EVOQUE valve. It offers both 
a transapical and transfemoral-transseptal approach. The EVOQUE valve offered 
enhanced maneuverability and depth control, and lower ventricular projection to 
avoid LVOT obstruction. Currently, the Edwards EVOQUE TMVR Early Feasibility 
Study (NCT02718001) is recruiting and will assess feasibility at 30 days. The 
RELIEF (Reduction or Elimination of Mitral Regurgitation in Degenerative or 
Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral 
Valve, NCT02722551) trial was stopped by the Edwards Company for further design 
validation. From the preliminary results presented, 13 patients have been treated 
with technical success of 92% and high mortality rate of 45% at 30 days [10, 27].
The Tiara (Neovasc Inc., Canada) valve is a bioprosthetic valve; it constitutes 
of bovine pericardial tissue, which is mounted inside a nitinol frame. It is self-
expanding and has a relatively large atrial skirt, which decreases the risk of paraval-
vular leaks. The first implant of Tiara valve was performed in Vancouver in 2014. 
The two major studies of the Tiara valves, TIARA-I (Early Feasibility Study of the 
Figure 1. 
Current transcatheter mitral valve replacement devices. A, CardiAQ/EVOQUE (Edwards Lifesciences Inc). B, 
Tiara (Neovasc Inc., Canada). C, FORTIS (Edwards Lifesciences Inc). D, Tendyne (Abbott Inc). E, intrepid 
(Medtronic Inc). F, caisson (LivaNova, UK). G, HighLife bioprosthesis and sub-annular implant (HighLife 
SAS, France). H, SAPIEN M3 (Edwards Lifesciences Inc). I, Cardiovalve (Cardiovalve, Israel). J, Navi-gate 
(NaviGate cardiac structures, Inc., CA). Obtained with permission from Testa et al. publication [10].
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Neovasc Tiara Mitral Valve System) (NCT02276547) and the latest TIARA-II (Tiara 
Transcatheter Mitral Valve Replacement Study), are actively enrolling patients, with 
promising preliminary results in 71 patients, mostly in functional MR (61%), show-
ing 94% technical success rate, with a mortality rate of 11.3% at 30 days [28, 29].
The FORTIS (Edwards Lifesciences Inc) valve is a self-expanding bioprosthetic 
valve of bovine pericardial tissue. The first FORTIS implant was performed in 2014. 
Preliminary results demonstrated outcomes of 13 patients with procedural success 
of 76.9%. In the early experience, the study was put on hold due to reported valve 
thrombosis [30].
The Tendyne MV system (Abbott Inc) is a self-expanding porcine pericardial 
valve, which is mounted on a nitinol stent. It is implanted using the transapi-
cal approach and the device is anchored to the annulus using apical tethers. The 
first Tendyne MV implant was performed in 2014. The Feasibility Study of the 
Tendyne Mitral Valve System for Use in Subjects With Mitral Annular Calcification 
(NCT03539458) of the first 100 patients showed that the technical success rate was 
97% with no periprocedural mortality and 30-day mortality rate of 6% [31]. Most 
patients (98.8%) had non-significant MR at 30 days [31]. Importantly, the SUMMIT 
(Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne 
Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation; 
NCT03433274) is an ongoing multi-center clinical trial randomizing patients to 
TMVR using the Tendyne valve versus conventional mitral valve surgery, with goal 
to enroll 1010 patients and expected completion year in 2026.
The Intrepid (Medtronic Inc) valve is a bovine pericardial valve fixed onto a 
self-expanding nitinol frame. The valve is implanted via transapical access in the 
majority of cases, but a transseptal approach is being developed. The first implant 
was performed in 2014. An initial pilot study enrolled 50 high-risk patients with MR 
and reported 96% success rate, 14% 30-day mortality rate and trivial-trace or mild 
residual MR at 30 days in all patients [32]. The multicenter randomized APOLLO 
(Transcatheter Mitral Valve Replacement With the Medtronic Intrepid TMVR 
System in Patients With Severe Symptomatic Mitral Regurgitation; NCT03242642) 
trial is still ongoing with patients randomized in a 1:1 fashion to the Intrepid valve 
versus conventional mitral valve surgery. Outcomes will be evaluated at 30 days, 
6 months, and 1 year, with up to 5 years follow-up duration, and estimated study 
completion date in 2025 [10].
The HighLife (HighLife SAS, France) valve is a 2-component system. The 
prosthetic valve is implanted in the mitral position and has an anchoring system 
placed by the trans-arterial retrograde approach in the sub-annular position [10]. 
Anecdotal initial cases are reported showing acceptable results of the valve [33]. A 
feasibility trial (NCT02974881) is still active.
The SAPIEN M3 (Edwards Lifesciences Inc) valve is a modified SAPIEN 3 valve. 
It is implanted using the transseptal approach. It uses nitinol docking system, which 
allows anchoring of device [10]. From the initial results of feasibility study in 15 
patients, technical success was achieved in 86.7%, MR reduction was achieved in 
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Summary of dedicated TAMR devices and primary outcomes of available early feasibility studies.
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93.3% and no mortality was reported at 30 days [34]. The ENCIRCLE trial is an 
ongoing study designed to assess the outcomes of the SAPIEN M3 device in 400 
patients (NCT04153292).
The Cardiovalve (Cardiovalve, Israel) valve is a bovine pericardial valve 
mounted on dual nitinol. It is usually implanted using the transseptal approach. The 
system allows multi-steerable catheter utilization, which provides better control 
of the device [10]. The AHEAD (European Feasibility Study of the Cardiovalve 
Transfemoral Mitral Valve System; NCT03339115) study is designed to assess the 
outcomes of Cardiovalve system in MR. The first 5 cases showed 100% of technical 
success with significant reduction of MR and absent or non-significant paravalvular 
leak [35].
The Cephea (Cephea Valve Technologies) system is a repositionable and recap-
turable frame valve and usually implanted using the transseptal approach. The 
frame structure allows adequate anchoring independent of the sub-valvular struc-
tures. The valve was tested in preclinical models with good performance at 90 days 
[36]. In addition, early experience with the Cephea device has been reported in 3 
patients after the first in-human case with 100% technical success [37, 38]. After 
a median 6-month follow-up, valve function, echocardiographic parameters and 
patients’ functional status were all favorable [38].
The AltaValve (4C Medical Technologies Inc) is a supra-annular device, which 
constitutes of bovine tissue mounted onto a nitinol frame. It is a self-expanding 
valve and implanted using the transseptal or transapical approach. Animal studies 
showed good performance, and a first-in-human case was performed in Canada in 
2018, with satisfactory results [10, 39].
The NaviGate (NaviGate Cardiac Structures Inc) valve is a self-expanding valve 
and constitutes of a nitinol stent frame and multiple annular winglets, to allow 
anchoring of the device in the mitral annular position. The valve is implanted using 
transapical approach. The first in-human valve implant was performed in 2015 in 
Chile [40]. After an initial interest of this valve in mitral valve position, the device 
was implanted in the tricuspid position for tricuspid regurgitation using transcath-
eter interventions with trans-jugular or trans-atrial approach [41].
9. Knowledge gaps and ideas for future research
With the recent advances in TMVR in the most recent years, there remain 
knowledge gaps and challenges in order to understand the disease and correlate 
clinical outcomes with this evolving technology. MR is often coexistent with other 
comorbidities, including valvular disease, such as tricuspid regurgitation, severe 
pulmonary hypertension, and atrial fibrillation, with significant and independent 
morbidity and mortality rates [4]. The role of these co-existing factors in this set-
ting is not well-known and should be evaluated in future research.
Studies have shown that TMVR is associated with higher rates of paravalvular 
leak compared to TAVR; this could be attributed to reduced anatomical support, 
asymmetrical annulus or asymmetric leaflets in mitral valve compared to aortic 
valve [4, 10]. Additionally, post-dilation of mitral prosthetic valve could potentially 
be challenging and risky; due to the close proximity of the mitral valve to the left 
circumflex artery, the conduction system and the aortic valve. In addition, efforts to 
avoid damage to sub-valvular structures should be pursued [4, 10]. Future improve-
ment of the dedicated TMVR-specific device design should address these anatomi-
cal issues. As we discussed in the previous section, different transcatheter devices 
have been designed for the treatment of MR (and, in some cases, for off-label 
treatment of mitral stenosis). Most of the TMVR technologies are still under clinical 
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investigation. Thus, data about their rates of structural deterioration and durability 
is limited [10].
At the present time, clinical outcomes we have are based on data of mainly the 
first and second generation prosthetic valves. Outcomes may potentially improve 
with newer generation devices, improvement in the process of patient selection, 
operators’ experience and innovations in procedural techniques [4]. Newer gen-
eration valves with repositionable and retrievable ability could be of benefit in 
certain patients. For example, the Lotus valve (Boston Scientific, Marlborough, 
Massachusetts) and Direct Flow (Direct Flow Medical Inc. Santa Rosa, California) 
valves have been successfully implanted in patients with severe MAC, however the 
outcomes of these valves should be assessed in future randomized clinical trials 
utilizing larger number of patients [11].
In conclusion, we have seen several advances in TMVR in the past decade with 
promising results. However, there remain challenges that need to be evaluated in 
future studies in order to optimize our procedural success, device evolution, and 
clinical outcomes to make this new cutting-edge technology available for high-risk 
patients.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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